Vertex Pharmaceuticals Inc. closed 10.71% below its 52-week high of $519.88, which the company reached on November 8th.

Vertex Pharmaceuticals Inc. closed 10.89% short of its 52-week high of $519.88, which the company achieved on November 8th.

News about Vertex Pharmaceuticals Inc., including commentary and archival articles published in The New York Times.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Harrow Health (HROW – Research Report), BridgeBio Pharma (BBIO – Research Report) and Merck & ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AbbVie (ABBV – Research Report) and Alkermes (ALKS – Research Report). Elevate ...

An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year ...

NetworkNewsWire Editorial Coverage NEW YORK, July 9, 2025 /PRNewswire/ -- Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the ...